SkinBioTherapeutics plc (AIM: SBTX), the AIM-listed life science business focused on skin health, has announced the appointment of Gill Whitty-Collins, former Senior Vice President of P&G Beauty at Procter & Gamble, as a Non-Executive Director. Whitty-Collins will also serve as Chair of the Remuneration Committee. The appointment brings over two decades of consumer brand leadership experience to the Manchester University spin-out's board, as the company prepares to report its FY26 results in November 2026.

Key Points

  • SkinBioTherapeutics plc (SBTX) — AIM-listed life science company focused on skin health
  • Gill Whitty-Collins, former P&G Beauty Senior Vice President, appointed as Non-Executive Director and Remuneration Committee Chair
  • Whitty-Collins spent 26 years at Procter & Gamble, leading global brands including Always, Pantene and Olay; holds no shares in SBTX at appointment
  • Investors should watch for the FY26 results announcement, expected during November 2026

Gill Whitty-Collins Brings 26 Years of Procter & Gamble Brand Leadership to SBTX Board

Whitty-Collins spent 26 years at Procter & Gamble, where she progressed from Marketing Director and General Manager to Senior Vice President, leading globally recognised consumer brands including Always, Pantene and Olay. Since leaving P&G, she has pursued a portfolio career as a keynote speaker, board member, consultant and coach, focusing on business leadership, brand building and gender equality. She is a Fellow of the RSA, Founder of The Brand Execs, and author of Why Men Win at Work and its follow-up, The How to Win at Work Book. She is a graduate of Cambridge University and is aged 56.

Remuneration Committee Chair Role and Board Diversity at SkinBioTherapeutics

In addition to her Non-Executive Director role, Whitty-Collins will chair the Remuneration Committee, adding formal governance responsibility to her commercial brief. Her broader board experience includes a current Trustee role at 50:50 Parliament, a previous Non-Executive Director position at Cellular Goods, and a Chairmanship of Swiss Netball. Her current directorship is listed as The Brand Execs International Limited, with Astrid Intelligence PLC noted among directorships held in the previous five years, as disclosed under AIM Rules for Companies Schedule Two requirements.

SkinBiotix Platform and Dual-Route Skin Health Strategy Underpin Commercial Ambition

SkinBioTherapeutics develops its products around its proprietary SkinBiotix® platform technology, originating from research by the translational dermatology team at the University of Manchester. The company pursues skin health through two commercial routes: topical creams addressing skin issues from the outside in, and oral supplements working from the inside out via the gut and brain. The group also operates a contract manufacturing and distribution arm covering skin health and broader healthcare products. The company has been listed on AIM since April 2017.

FY26 Results Expected in November 2026 as SBTX Eyes Growth Delivery

The announcement confirms that SkinBioTherapeutics intends to report its FY26 results during November 2026, with a formal notice of results to follow in due course. Chair Alyson Levett stated in the announcement that Whitty-Collins brings "an important additional commercial perspective" and that the board looks forward to "build on the progress made and focus on delivering the group's growth potential." Investors may be watching the forthcoming results closely for evidence of commercial momentum from the company's dual-route product strategy.